Posted by Michael Wonder on 23 Jan 2023
China’s drug pricing policy impedes biotech profits
23 January 2023 - Beijing’s push to boost the sector has been undermined by reimbursement rules.
China’s biotech companies are struggling to become profitable as Beijing’s pricing policy undermines attempts to build a homegrown pharmaceutical industry through capital markets.
